ALK
Gli inibitori di ALK sono composti che mirano specificamente e inibiscono la chinasi del linfoma anaplastico (ALK), una tirosina chinasi recettoriale coinvolta nello sviluppo e nella progressione di alcuni tipi di cancro, inclusi il carcinoma polmonare non a piccole cellule e il neuroblastoma. Inibendo ALK, questi composti bloccano le vie di segnalazione che promuovono la crescita e la sopravvivenza delle cellule tumorali. Presso CymitQuimica, offriamo inibitori di ALK per supportare la tua ricerca in oncologia, terapie mirate contro il cancro e trasduzione del segnale.
Trovati 152 prodotti per "ALK".
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK-IN-24
CAS:ALK-IN-24 is an orally active ALK inhibitor with an IC50 value of 1.7 nM. It also inhibits the insulin receptor kinase, with an IC50 value of 6 nM. ALK-IN-24 suppresses the proliferation of lung adenocarcinoma cells and hinders ALK-driven tumor growth in xenograft mouse models. It is applicable for research related to non-small cell lung cancer.Formula:C26H30ClN7O3SPeso molecolare:556.08ALK-IN-35
CAS:ALK-IN-35 is an ALK degrader with an IC50 of 0.74 nM. It inhibits ALK kinase activity, increases the solvent-accessible surface area of hydrophobic residues near the ALK binding pocket, promotes the formation of partially unfolded ALK conformations, and induces proteasome-mediated degradation of ALK. ALK-IN-35 effectively inhibits cancer cell proliferation and is applicable in research related to non-small-cell lung cancer.Formula:C36H45ClN7O3PPeso molecolare:690.21(E)-Belizatinib
CAS:(E)-Belizatinib ((E)-TSR-011) (compound 36) is the (E)-isomer of Belizatinib, and serves as a potent, highly selective, and orally active inhibitor of anaplastic lymphoma kinase (ALK), with an enzymatic IC50 of 0.005 μM and a cellular IC50 of 0.048 μM. The compound exhibits over 61-fold selectivity against JAK2, SRC, and IGF1R, and demonstrates excellent efficacy and pharmacokinetic properties in rats and dogs. (E)-Belizatinib is applicable for research in ALK-driven cancers.Formula:C33H44FN5O3Peso molecolare:577.75CEP-28122 mesylate hydrochloride
CAS:CEP-28122 mesylate hydrochloride, a diaminopyrimidine derivative, is a potent, selective, and orally bioavailable ALK inhibitor with an IC50 of 1.9 nM, exhibiting antitumor and good pharmacokinetic activity [1].Formula:C29H40Cl2N6O6SPeso molecolare:671.64ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Formula:C26H29ClN8O3SColore e forma:SolidPeso molecolare:569.08PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Formula:C23H23FN6O4Colore e forma:SolidPeso molecolare:466.46CEP-14083
CAS:CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.Formula:C31H30N6O2Colore e forma:SolidPeso molecolare:518.61CDD-1115
CAS:CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.Formula:C32H30N6O3Colore e forma:SolidPeso molecolare:546.619TGF-βRI inhibitor 3
CAS:TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.Formula:C21H21NO4Colore e forma:SolidPeso molecolare:351.396DA-0157
CAS:DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.Formula:C31H43BrN7O2PColore e forma:SolidPeso molecolare:656.597Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purezza:99.98%Colore e forma:SolidPeso molecolare:447.41Ref: TM-T9414
1mg114,00€5mg268,00€1mL*10mM (DMSO)303,00€10mg439,00€25mg879,00€50mg1.395,00€100mg1.873,00€AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Formula:C19H15N5Purezza:99.61%Colore e forma:SolidPeso molecolare:313.36Ref: TM-T10426
1mg94,00€5mg222,00€1mL*10mM (DMSO)245,00€10mg356,00€25mg690,00€50mg1.035,00€100mg1.431,00€
